PubMed Health⌕ Search

Biomedical subjects

M Abbas

Publications and source records attributed to M Abbas.

41 records · Page 3Linked to original sources
PubMedDate not supplied

MIB-1 index, S-phase fraction, mitotic figure count, and SBR histologic grading in invasive breast carcinoma: a comparative study.

Proliferative activity has been proven to be of prognostic significance in breast carcinoma. This study was performed to compare the different proliferative fractions in the Egyptian population and to define the most suitable one for daily routine use in our surgical pathology laboratories. The proliferative activity of 63 invasive ductal carcinomas was evaluated by immunohistochemical staining of paraffin-embedded tissue sections with MIB-1 rabbit polyclonal antibody and the heat-induced epitope retrieval method, flow cytometric determination of the S-phase fraction (SPF) on frozen tissues, and estimation of the Scarff-Bloom-Richardson (SBR) grading and mitotic figure count (MFC) on hematoxylin and eosin-stained tissue sections. Fifty-two percent of invasive ductal carcinoma were aneuploid. The mean values of MIB-1 index, SPF, and MFC were 17.7 +/- 12.3, 4.9 +/- 3.8, and 5.2 +/- 4.5, respectively, for diploid tumors; while for aneuploid tumors, they were 58.6 +/- 31.9, 19.9 +/- 12.2, and 23.1 +/- 16.9, respectively. These values were significantly higher in aneuploid versus diploid tumors (p < 0.0001). A close correlation was found between MIB-1 index, SPF, MFC, and SBR grading (p < 0.0001). In conclusion, in surgical pathology laboratories that cannot afford the costs of flow cytometry and/or immunostaining, proper SBR grading and MFC can provide an estimation of the proliferation fraction similar to the flow cytometric SPF and MIB-1 immunostaining.

Antigens, Nuclear↗
PubMedDate not supplied

[Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].

AIM: The objective of the study was to estimate the cost of first line chemotherapy in metastatic colorectal cancer treated in the Gustave-Roussy Institute. Patients were randomized in the study FFCD 9601 with four schedules of treatment: Tomudex(R), 5FU weekly, LV5FU2 with low dose of folinic acid and LV5FU2 with high dose of folinic acid. PATIENTS AND METHODS: Thirty three patients were included prospectively from March 1997 to April 1999. Healthcare costs took into account drug-regimen related costs (cost of the drugs and its preparation, drug administration, laboratory tests, transport from and to hospital), non-drug-regimen related hospitalization costs (treatment of chemotherapy related side effects, radiologic tests, hospital outpatient visits, transport from and to hospital) and surgery costs. Costs were derived from the accounting system in the Gustave-Roussy Institute. Non medical costs were not taken into account in this study. RESULTS: The median overall cost per 4 weeks was 6,343 FF with LV5FU2 low dose, 9,968 FF with LV5FU2 high dose, 15,340 FF with 5FU weekly and 28,810 FF with Tomudex(R). This overcost is explained by a more expensive price and greater toxicity: 12 grade 3-4 toxicity and 9 hospitalizations (including one in intensive care unit for the 8 treated patients) for Tomudex(R) despite a lower cost for the administration of the drug. Weekly 5FU was the most expensive among the 5FU schedules because of its dose and frequency of administration. CONCLUSIONS: The cost of first line chemotherapy in metastatic cancer colorectal is high (6,000 FF minimum per 4 weeks of treatment). Tomudex, a recent and expensive drug, seems to be more toxic. In this study, toxicity was probably overestimated due to the small number of patients. More patients are necessary in order to better estimate the cost of toxicity of these chemotherapies.

Antimetabolites, Antineoplastic↗